NewAmsterdam Pharma Company N.V. reported a net loss of $39,527,000 for the three months ended March 31, 2025, a significant improvement from the $93,767,000 net loss in the same period last year. Revenue increased to $2,978,000 from $1,401,000, primarily due to development cost contributions from a partner. Operating expenses rose, but this was offset by substantial gains from fair value changes in earnout and warrants, and increased interest income.

NewAmsterdam Pharma reported a net loss of $241.6 million for the full year 2024, an increase from $176.9 million in 2023. The company's revenue increased to $45.6 million in 2024 from $14.1 million in 2023, primarily due to a clinical success milestone and development cost reimbursement. Cash and cash equivalents significantly increased to $771.7 million by year-end 2024, driven by successful financing rounds.

NewAmsterdam Pharma reported positive results from its Phase 3 BROOKLYN trial, extended its US IP protection for obicetrapib into 2043, and has a strong cash position of $430.7 million. Topline data from the BROADWAY trial is expected in Q4 2024, and the TANDEM trial data is expected in Q1 2025.